Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Eli Lilly becomes first pharma firm to join $1 trillion club The companys stock has zoomed this year, driven by the explosive growth of the weight-loss drug market
Orforglipron, developed by Eli Lilly, is the first non-peptide GLP-1R agonist to undergo advanced clinical trials
In addition, all participants had at least one documented cardiovascular condition at baseline, limiting the generalizability of the findings to patients without pre-existing cardiovascular disease
2010 Jun 30
US$ 23.56
US$ 27.39
US$ 27.99
US$ 24.77
